Arcus Biosciences, Inc.
RCUS
$9.34
-$0.20-2.10%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 26.00M | 48.00M | 39.00M | 145.00M | 31.00M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 26.00M | 48.00M | 39.00M | 145.00M | 31.00M |
Cost of Revenue | 101.00M | 123.00M | 10.00M | 109.00M | 93.00M |
Gross Profit | -75.00M | -75.00M | 29.00M | 36.00M | -62.00M |
SG&A Expenses | 28.00M | 30.00M | 30.00M | 32.00M | 29.00M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 129.00M | 153.00M | 145.00M | 141.00M | 122.00M |
Operating Income | -103.00M | -105.00M | -106.00M | 4.00M | -91.00M |
Income Before Tax | -93.00M | -92.00M | -93.00M | -4.00M | -80.00M |
Income Tax Expenses | 1.00M | -- | -- | -- | 1.00M |
Earnings from Continuing Operations | -94.00M | -92.00M | -93.00M | -4.00M | -81.00M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -94.00M | -92.00M | -93.00M | -4.00M | -81.00M |
EBIT | -103.00M | -105.00M | -106.00M | 4.00M | -91.00M |
EBITDA | -100.00M | -103.00M | -104.00M | 7.00M | -88.00M |
EPS Basic | -1.03 | -1.01 | -1.02 | -0.05 | -1.08 |
Normalized Basic EPS | -0.63 | -0.63 | -0.64 | 0.12 | -0.67 |
EPS Diluted | -1.03 | -1.01 | -1.02 | -0.05 | -1.08 |
Normalized Diluted EPS | -0.63 | -0.63 | -0.64 | 0.12 | -0.67 |
Average Basic Shares Outstanding | 91.70M | 91.40M | 91.10M | 86.20M | 75.00M |
Average Diluted Shares Outstanding | 91.70M | 91.40M | 91.10M | 86.20M | 75.00M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |